Your genetic peptide profile helps determine which path makes sense
A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinsons disease by increasing expression of BNDF
Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation
How GLP-1 Improves Fat Distribution: Most people tend to accumulate visceral fat around their midsection, which not only affects appearance but also increases the risk for conditions like heart disease, type 2 diabetes, and inflammation
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
When to Start GLP-1 After Gastric Bypass: Timing, Diet, and Success Strategies Wondering when to start GLP-1 after gastric bypass
